Licensing agreement means COVID-19 therapeutic, molnupiravir, said to cut COVID-19 hospitalizations and death in high-risk patients in half, will be available for generic manufacture in 105 countries, dramatically increasing access and affordability in low- and middle-income countries. NEW YORK, NY, THURSDAY, OCTOBER 28TH, 2021 – Members of the Interfaith Center on Corporate Responsibility and shareholders […]
- Press Releases
- Equitable Access to Medicine
- Health Equity